Build my stack
Home · Guides · Oral BPC-157

Oral BPC-157: Do Capsules and Pills Actually Work?

Ready to buy? the vendor scorecard ranks every seller we review on lab tests, shipping and price, with reader codes.

Oral BPC-157 has animal data for gut targets and no human data showing how much of a capsule reaches the blood. Reviews from the group that developed it describe the peptide as stable in human gastric juice, but stability is not absorption: the only bioavailability figures we found were measured after intramuscular injection, about 14 to 19 percent in rats and 45 to 51 percent in dogs. The one registered human oral trial we found (NCT02637284, 1 mg tablets, 42 volunteers planned) has no posted results, and no human trial compares capsules with injection. BPC-157 is not FDA-approved, and the 30 October 2026 HHS policy (91 FR 68526) concerns prescription compounding, not research-use capsules.

Updated 2 November 2026. Animal data is labelled as animal data throughout, and where no human trial exists this page says so. Every study, regulatory and date claim is tied to a source in the list at the end, checked 2 November 2026. This is a summary of what sources report, not advice. Research use framing.

Disclosure: affiliate links below may earn the Bureau a commission at no cost to you.

Oral BPC-157 at a Glance

Question What the sources show Evidence type
Does it survive human gastric juice? Reported stable by reviews from the group that developed it; a 2026 review repeats "unusual stability in gastric juice" Review claims, original experiment not opened
Does an oral dose reach the blood? No measurement found. The 2022 rat and dog study tested intravenous and intramuscular routes only None found
Measured bioavailability, any route Intramuscular only: about 14 to 19 percent in rats, 45 to 51 percent in dogs Animal, 2022
Effect on the gut after oral dosing Rats given it in drinking water gained weight and had larger villi and stronger bowel joins after surgery Animal, one research group, 2009
Human oral trial NCT02637284: 1 mg tablets, 42 volunteers planned, status unknown, no results posted Registered, no results
Oral against injection in people No trial found None
Human data on injected BPC-157 One retrospective knee series (7 of 12 reported relief for over 6 months) and a two-person intravenous safety pilot Human, uncontrolled

The Bioavailability Problem

Best vendor for BPC-157 right now: Amino Club

10mg vial, $39.99 per vial ($4.00 per mg), list price checked 2026-09-08. The vendor Bureau readers order from most, with a batch COA on every product page. Partner code 100 at checkout takes 20% off there, and keeps the order counted for the Bureau. Research use only.

Check price at Amino Club Compare all vendors Black Friday 40% off, applied by our link (was 20%) code 100 ends 30 Nov

BPC-157 is a synthetic peptide of 15 amino acids (sequence GEPPPGKPADDAGLV) with a molecular weight of 1,419 daltons. A swallowed peptide meets stomach acid and digestive enzymes first, then has to cross the intestinal wall to reach the blood.

The usual counter-argument is stability. Reviews from the group that developed the compound describe BPC-157 as stable in human gastric juice and usable without a carrier, and a 2026 narrative review of its formulation science says it "exhibits unusual stability in gastric juice". We could not open the original stability experiment, and the reviews we read come from the developing group or repeat its work, so treat the claim as reported rather than independently replicated.

Stability is not absorption. The same 2026 review says the human pharmacokinetic profile "remains critically undercharacterized" and that the peptide "lacks bcs classification data, permeability characterization, and formal excipient compatibility studies". The one published exposure study is a 2022 rat and dog study, which tested intravenous and intramuscular dosing only. It found an elimination half-life under 30 minutes and an intramuscular bioavailability of about 14 to 19 percent in rats and 45 to 51 percent in dogs. That is a result for injection in animals, and it says nothing about swallowing a capsule. Oral percentages that appear on vendor and clinic pages (we saw figures such as 15 to 30 percent) have no human measurement behind them that we could find.

Oral Against Injection: What Human Data Exists

We found no trial that compares oral with injected BPC-157 in people. What exists is small and uncontrolled:

  • Oral, registered but unreported. ClinicalTrials.gov lists NCT02637284, a Phase 1 study of 1 mg BPC-157 tablets in healthy adults aged 18 to 35: 42 volunteers planned, single doses of 1, 3 or 6 tablets, then 3 tablets every 8 hours for 2 weeks, with pharmacokinetics (Cmax, Tmax, AUC, half-life) as secondary outcomes. The record was last verified in October 2015, its status is unknown and it has no posted results.
  • Injected, retrospective. A 2025 systematic review found 36 studies of BPC-157 in orthopaedic sports medicine, 35 preclinical and 1 clinical. The clinical study was a retrospective series of intra-articular injections for chronic knee pain, in which 7 of 12 patients reported relief for over 6 months. The review found no clinical safety data.
  • Intravenous, two people. A 2025 pilot infused 10 mg and then 20 mg of BPC-157 into two participants and reported no adverse effects on the tested biomarkers. The 2026 formulation review counts fewer than 30 subjects across three uncontrolled pilot studies in total.

USADA states that there are no human clinical trials establishing efficacy for the use of BPC-157. So everything below about which route suits which target is reasoning from animal data and pharmacology, not a human result.

Gut Use: Where the Oral Animal Data Sits

The gut is the target for which swallowing makes sense on its face, because a capsule does not need to enter the blood to reach the gut lining. That is logic, not a measured result. The animal data is real but narrow. In a 2009 rat study of short bowel syndrome, BPC-157 at 10 micrograms or 10 nanograms per kilogram was given in drinking water (12 ml per rat per day) or by intraperitoneal injection. Treated rats kept gaining weight, their villus height, crypt depth and muscle thickness increased, and their bowel joins were stronger. The oral and injected groups both showed it, so the study does not show that oral is better or worse than injection. Reviews by the same group describe protection in rat models of alcohol and anti-inflammatory drug lesions and healing of bowel joins and fistulas. Tendon and ligament claims are a separate question, covered in peptides for tendon repair.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Those reviews also describe clinical trials for inflammatory bowel disease under the code PL 14736. The 2026 formulation review says no Phase II trial of BPC-157 has been completed, and we found no full published results, so there is no human evidence for the gut claim yet. Our BPC-157 guide covers the animal evidence base for gut protection in more detail.

For a tendon, a ligament or a joint, the target is distant tissue. An oral dose would first have to reach the blood, and that step has never been measured in a person.

Get the Dispatch

One research note, one vendor deal, once a week. Free dosing guide on confirm.

Double opt-in. Unsubscribe with one click. Research use only.

Capsules, Nasal Spray and the Other Formats

Capsules and tablets

The standard oral format, commonly sold at 250 or 500 micrograms per capsule. Some are enteric coated to release in the small intestine. Arginate salt versions are marketed as more stable than the acetate form. The capsule section below covers what is inside one, whether the coating earns its place and how to judge a product.

Nasal spray

Intranasal delivery is a different route, not a variation on swallowing. The nasal mucosa is thin and well supplied with blood vessels and skips the gut. How well a peptide crosses it varies by molecule and formulation, and for BPC-157 we found no published human data on the nasal route. It is plausible but unmeasured.

Sublingual and buccal

The same idea: hold the compound against the mouth lining instead of swallowing it. Contact time is short and we found no BPC-157 data for it.

Injection

The route behind the only measured exposure data, though those measurements are intramuscular, in rats and dogs, and we found no subcutaneous or human figure. Most community practice assumes subcutaneous injection.

Lyophilised vials cover both routes

A vial of powder can be reconstituted for injection or taken orally in solution, which is why it is the more flexible purchase. Suppliers scored in the 2026 scorecard.

Pantheon BPC-157 Apollo BPC157 10mg

BPC-157 Capsules: What Is Actually In Them

A BPC-157 capsule is a two piece shell, gelatin or HPMC, holding a small amount of peptide and a much larger amount of filler. A 500 microgram capsule is half a milligram of BPC-157 in a shell that holds several hundred milligrams, so the rest is bulking agent such as microcrystalline cellulose or rice flour. That is unavoidable at this dose, and it is why two capsules that look identical can differ greatly in what they contain.

BPC-157 is not an approved drug. USADA states that the US Food and Drug Administration has not approved it for human clinical use. FDA's page on bulk substances that may present significant safety risks now lists BPC-157 under "Bulk drug substances nominated but withdrawn" (page content current as of 22 April 2026) and says compounded drugs containing it "may pose risk for immunogenicity for certain routes of administration" and that FDA "has identified no, or only limited, safety-related information for the proposed routes of administration".

On 30 October 2026 HHS published a notice (91 FR 68526) saying it "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A". The notice calls it an interim policy, says it "is not binding on HHS or the public", and took comments for two weeks after publication; they closed on 13 November 2026, and as of 14 November HHS had published no final version. Per our explainer of the policy text, BPC-157 is one of six peptides listed, its listed forms include oral, and one of ten conditions expects a compounder of an oral form to keep documentation that the specific formulation reaches adequate oral bioavailability in humans, which is the open question this page is about. The policy covers compounding on a prescription for an individual patient. It is not an FDA approval and does not extend to research-use-only capsules or vials. BPC-157 is also prohibited for tested athletes: USADA places it on the WADA Prohibited List in class S0, non-approved substances. Everything described on this page is sold for research use, and nothing here is an instruction to take it.

Enteric coating, and whether it helps

An enteric coating is a polymer film that stays intact in stomach acid and dissolves in the higher pH of the small intestine. We found no study of an enteric coated BPC-157 product, so what follows is reasoning. If the target is the lower gut, a coating is sensible design because it carries the peptide past the stomach. If the target is the stomach itself, it carries the compound straight past its own target. If the target is systemic, a coating addresses survival in the stomach, and the unmeasured step is crossing the intestinal wall, which no coating is known to change. The stability claim vendors lean on is an argument that a coating is unnecessary, not that it works.

The arginate salt

BPC-157 is normally supplied as the acetate salt, which is what the studies above and almost every vial use. The arginate salt, sold as BPC-157 arginate or "stable" BPC-157, swaps the counterion for arginine, and vendors market it as more soluble and more stable. We found no published study that compares arginate with acetate for stability or absorption in animals or people, and none that measures plasma BPC-157 after an oral dose of either. If a vendor charges several times more for it and cites trials, ask which trials, because we could not find them.

Best BPC-157 capsules: how to judge a product

No capsule has been tested against an outcome in a human trial, so "best" can only mean best made and best documented. Six things separate a product worth a look from one that is not.

  • A stated dose in micrograms. Not a proprietary blend, not "BPC-157 complex". If the label will not say how much peptide is in the capsule, you cannot judge it.
  • A certificate for the finished capsule lot. Many capsule sellers publish a certificate for the raw powder their supplier shipped, which says nothing about what went into the shell. A lot specific certificate on the finished product is the strongest signal on the page.
  • Identity and purity by a named method. HPLC for purity, mass spectrometry for identity, with the actual numbers shown rather than a pass badge. The testing guide covers what those documents do and do not prove.
  • The salt form named. Acetate or arginate, stated plainly.
  • Nothing bundled in that obscures the dose. Capsules that mix BPC-157 with glutamine, zinc carnosine or a gut blend make the peptide amount harder to see.
  • Price worked out per milligram. Sixty capsules at 250 micrograms is 15 mg. Sixty at 500 is 30 mg. Similar bottle prices can hide a twofold difference in strength.

Capsules against injection against nasal spray

Capsules and pills Injection Nasal spray
Absorption into blood Never measured in a person or, as far as we found, in an animal Measured only for intramuscular dosing in rats (about 14 to 19 percent) and dogs (about 45 to 51 percent) Never measured for this compound
Delivery to the gut lining Direct contact, which is the whole argument for the format Only whatever circulates back None expected
Human evidence No published result. One registered oral Phase 1 trial with no posted results Small and uncontrolled: one retrospective knee series, one two-person intravenous pilot None found
Animal evidence Drinking water dosing in rat gut models, one research group 35 preclinical musculoskeletal studies in the 2025 review; we did not tabulate their routes None found
Certificate situation Often raw material, not finished lot Usually per lot on the vial Often raw material, and dose per spray is often unstated
Where the evidence points Gut targets, from animal data only Other targets, because it is the route with any measurements Nowhere yet

BPC-157 Pills, Tablets and Capsules: What the Words Mean

"BPC-157 pills" usually means the same product as capsules. Strictly, a pill is any small solid oral dose, a capsule is a shell filled with loose powder, and a tablet is powder compressed with binders. Almost everything sold as BPC-157 pills is a capsule. A capsule can be opened and its contents dissolved or held under the tongue, which is how people improvise a sublingual dose, and a tablet cannot. A sublingual troche is a separate format designed to dissolve in the mouth, and it is not meant to be swallowed.

The word "pills" also pulls in shoppers who read the product as a supplement. BPC-157 is an unapproved compound, and a bottle styled like a multivitamin deserves a harder look at its certificate, not less of one.

Dosing Oral BPC-157

Because absorption is unquantified, oral dose conventions are not derived from anything. Community practice, as reported, quotes the same 250 to 500 micrograms a day as injection, sometimes doubled on the reasoning that part is lost. That reasoning does not hold together: if oral bioavailability is low, matching the injected amount delivers a small fraction and doubling it delivers a slightly larger small fraction, and if the effect is local to the gut, bloodstream absorption is beside the point. The rat studies used 10 micrograms and 10 nanograms per kilogram, a thousandfold range that both reported effects, and the registered human oral trial used 1 mg tablets. No human oral dose has been established. The dosage calculator handles the injectable arithmetic, which is at least calculable, and our BPC-157 buying guide covers sourcing. Reported injectable schedules are on the BPC-157 dosage page.

Powder Versus Capsules on Cost

A 10 mg vial of lyophilised BPC-157 contains 10,000 micrograms, which at 500 micrograms a day is twenty days. Sixty capsules at 500 micrograms is 30,000 micrograms. Work out the price per milligram for each and compare, because the packaging and retail chain behind a capsule is part of what you pay for.

Powder is also more flexible: the same vial can be reconstituted for injection or taken orally in solution, so the route decision does not have to be made at purchase. The other consideration is paperwork. Vial certificates are ordinarily issued per lot, while capsule products often give a certificate for the raw material, which does not verify what went into the shell. If the target is the gut, the KPV page covers a second compound with its own gut literature.

What To Do With All This

Three conclusions follow from the evidence rather than the marketing.

  • Gut target: the oral route is the one with animal data and a plausible mechanism, from one research group, with no completed human trial.
  • Distant tissue target (tendon, ligament, muscle, joint): oral absorption is the unmeasured step, and injection is the route with any measurements, in animals.
  • Undecided: lyophilised powder keeps both routes open, usually costs less per milligram and usually comes with better paperwork than capsules.

What the evidence does not support is treating oral and injected BPC-157 as interchangeable at the same dose, because the step that would make them equivalent has never been measured. If you are planning a protocol of any kind, the stack builder sets out route and timing alongside compound choice.

Key Takeaways

  • BPC-157 is a 15 amino acid peptide of 1,419 daltons; reviews from its developing group report it is stable in human gastric juice
  • Stability in gastric juice is not absorption, and no oral bioavailability measurement exists that we could find
  • The only measured bioavailability is intramuscular: about 14 to 19 percent in rats and 45 to 51 percent in dogs
  • Oral animal data is for gut targets, from one research group; no completed human trial supports it
  • The one registered human oral trial (NCT02637284) has no posted results, and no trial compares oral with injected BPC-157
  • Human data on injected BPC-157 is one retrospective knee series and a two-person intravenous pilot
  • Nasal and sublingual routes are plausible and unmeasured for this compound
  • BPC-157 is not FDA-approved and is prohibited for tested athletes under WADA class S0; the 30 October 2026 HHS policy concerns prescription compounding, not research-use products

Frequently Asked Questions

Does oral BPC-157 actually work?

No human trial shows that it does. The animal evidence for oral dosing is for gut targets: in one rat study of short bowel syndrome, BPC-157 given in drinking water and BPC-157 given by injection both improved weight gain and gut measurements. For tendon, joint or muscle, nobody has measured how much of an oral dose reaches the blood, and there is no human trial of capsules.

Does BPC-157 survive stomach acid?

Reviews from the group that developed it describe BPC-157 as stable in human gastric juice, and a 2026 review of its formulation science repeats that it shows unusual stability in gastric juice. We could not open the original experiment, so treat the claim as reported by that group. Surviving the stomach does not show that the peptide crosses the intestinal wall into the blood.

What is the bioavailability of oral BPC-157?

Unknown. We found no measured oral bioavailability for BPC-157 in people. The only measured values are for intramuscular injection: about 14 to 19 percent in rats and 45 to 51 percent in dogs, from a 2022 study that did not test an oral route. Oral percentages quoted on vendor sites are estimates, and we could not trace any of them to a measurement.

Is oral BPC-157 as good as injection?

No human trial compares the two. Injected BPC-157 has the only exposure measurements, in rats and dogs, plus a few small uncontrolled human reports. Capsules have no measured blood levels at all. The oral animal data is for gut targets, so the gut is where the oral route has a plausible case, and for other tissues injection is the route with any measurements behind it. This is a summary of the evidence, not a recommendation.

Is oral BPC-157 good for the gut, ulcers or IBS?

The evidence is animal only. Rat studies, mostly from one research group, report gut effects after dosing in drinking water, and that group describes trials of the compound for inflammatory bowel disease under the code PL 14736. A 2026 review says no Phase II trial of BPC-157 has been completed, and we found no full published results. We found no human evidence that oral BPC-157 helps ulcers, IBS or leaky gut.

What dose of oral BPC-157 is used, and how long does it take?

No human oral dose has been established. Amounts of 250 to 500 micrograms a day are widely quoted in community use, copied from injection habits rather than from a measurement. The only registered human oral trial used 1 mg tablets, either 1, 3 or 6 tablets once or 3 tablets every 8 hours for 2 weeks, and has no posted results. The rat studies used 10 micrograms per kilogram and 10 nanograms per kilogram. We found no human data on food, timing or how long an oral dose takes to act.

Is BPC-157 nasal spray better than capsules?

It is a different route rather than a variation, because nasal mucosa is thin and well supplied with blood vessels and skips the gut. That makes it a real delivery option for some peptides. For BPC-157 we found no published human data on the nasal route, so it is plausible but unmeasured, and capsules are equally unmeasured.

Is oral BPC-157 legal or FDA-approved?

It is not FDA-approved. On 30 October 2026 HHS published an interim, non-binding policy saying it does not intend to take enforcement action against a State-licensed pharmacy, Federal facility or licensed physician that compounds BPC-157, oral forms included, when listed conditions are met. It covers prescription compounding, not research-use capsules or vials. BPC-157 is also prohibited for tested athletes under the WADA Prohibited List class S0.

Sources (checked 2 November 2026)

  1. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol, 2022. Intravenous and intramuscular routes only; molecular weight 1419 Da; elimination half-life under 30 minutes. PMID 36588717. Checked 2 November 2026.
  2. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics, 2026. PMID 42198317. Checked 2 November 2026.
  3. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J, 2025. PMID 40756949. Checked 2 November 2026.
  4. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med, 2025. PMID 40131143. Checked 2 November 2026.
  5. ClinicalTrials.gov, PCO-02 Safety and Pharmacokinetics Trial (oral BPC-157 tablets, healthy volunteers), record last verified October 2015, no results posted. NCT02637284. Checked 2 November 2026.
  6. Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats. Dig Dis Sci, 2009. Animal study, drinking water and intraperitoneal dosing. PMID 19093208. Checked 2 November 2026.
  7. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des, 2011. Review by the group that developed the compound. PMID 21548867. Checked 2 November 2026.
  8. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. Surg Today, 2007. PMID 17713731. Checked 2 November 2026.
  9. FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 22 April 2026; BPC-157 listed under substances nominated but withdrawn). fda.gov. Checked 2 November 2026.
  10. HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Federal Register notice 2026-22192, 91 FR 68526, 30 October 2026. federalregister.gov. Checked 2 November 2026.
  11. USADA, BPC-157: Experimental Peptide Creates Risk for Athletes. usada.org. Checked 2 November 2026.
  12. Peptide Bureau, HHS peptide policy explainer, which reads the 16-page HHS policy text (BPC-157 routes in Appendix B, the ten conditions, the oral bioavailability documentation condition). The HHS PDF returned an access error on 2 November 2026, so those details are carried from that explainer. Checked 2 November 2026.
PB
The Peptide Bureau editorial desk. Peptide Bureau is a small independent research team covering peptide dosing, safety and vendors. We are not clinicians; nothing here is medical advice. How the Bureau works.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes